3-(2-AMINOETHYL)INDOLE AND -INDOLINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Abstract: A compound of formula (I) or a pharmaceutically accept­ able salt thereof: wherein: R₁ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy or halogen; R₂ and R₃ are both hydrogen or together represent a bond; R₄ is selected from C₁₋₆ alkyl, phenyl, phenyl C₁₋₄, alkyl, COR₈ where R₈ is hydroxy, C₁₋₆ alkoxy or NR₉R₁₀ where R₉ and R₁₀ are independently hydrogen or C₁₋₄ alkyl and CH₂OR₁₁ where R₁₁ is hydrogen, C₁₋₄ alkyl or C₁₋₄ alkanoyl; R₅ is hydrogen, C₁₋₆ alkyl or phenyl C₁₋₄ alkyl; R₆ is phenyl C₁₋₇ alkyl in which the phenyl moiety is opti­ onally substituted by one or two of halogen, ortho-nitro, meta-or para-methoxy, methyl or NR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently hydrogen or C₁₋₆ alkyl or R₁₂ and R₁₃ together are C₂₋₆ polymethylene or the phenyl moiety is 3,4-­ disubstituted by methylenedioxy or ethylenedioxy; and R₇ is hydrogen or C₁₋₄ alkyl, processes for its preparation and its use as a pharmaceutical.

Description: This invention relates to compounds having pharmacological activity, to a process for their preparation and their use as pharmaceuticals. Various 3-(2-aminoethyl)indoles are described in the literature. Thus, for example, GB-A-781 390 describes the preparation of 3-(2-aminoethyl)indoles by the reduction of a 3-indoleglyoxylylamide of the formula: wherein R a is hydrogen, or an aryl, substituted aryl, aralkyl, or substituted aralkyl radical, preferably containing not more than fifteen carbon atoms, or an alkyl radical of not more than eight carbon atoms, R b is hydrogen or a halogen atom, or a cyano, carboxy, carbalkoxy (wherein the alkyl group contains 1-8 carbon atoms), dialkylamino or alkyl or alkoxy group (containing 1-8 carbon atoms), or a substituted or unsubstituted aryl, aralkyl, aryloxy, benzyloxy or benzhydryloxy group, an acyloxy (wherein the acyl group is from an organic carboxylic acid containing from 1-8 carbon atoms) or a fused arylene radical, R b being preferably a group of not more than fifteen carbon atoms, n is zero or an integer from one to four, and Z is a primary secondary or tertiary amido radical suitably derived from ammonia, a primary or secondary alkyl, cycloalkyl, aralkyl or aryl amine or a heterocyclic amine such as piperidine, morpholine, thiamorpholine, pyrrolidine, hexamethyleneimine, tetrahydroisoquinoline or hexahydroisoquinoline. Examples of 3-(2-aminoethyl)indoles prepared by this route include 7-methoxy-2-benzyl-3-(2-N-benzylaminoethyl)indole and 2-hexyl-3-(2-N-phenethylaminoethyl)indole. U.S. Patent No. 4,021,431 discloses 1-acyl-3-(amino-lower alkyl) indoles which are described as possessing anti-inflammatory activity. FR-A-2,181,559 discloses certain indole derivatives which are described as possessing activity for treating diseases of the nervous system. J. Heterocyclic Chem . (1981), 18 , 1269 discloses certain indole derivatives which are described as possessing cardiovascular and anti-Parkinson activity. A group of compounds has now been discovered to have anti-hypoxic activity and/or activity against cerebral oxygen deficiency. Accordingly, the present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R₁ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy or halogen; R₂ and R₃ are both hydrogen or together represent a bond; R₄ is selected from C₁₋₆ alkyl, phenyl, phenyl C₁₋₄ alkyl, COR₈ where R₈ is hydroxy, C₁₋₆ alkoxy or NR₉R₁₀ where R₉ and R₁₀ are independently hydrogen or C₁₋₄ alkyl and CH₂OR₁₁ where R₁₁ is hydrogen, C₁₋₄ alkyl or C₁₋₄ alkanoyl; R₅ is hydrogen, C₁₋₆ alkyl or phenyl C₁₋₄ alkyl; R₆ is phenyl C₁₋₇ alkyl in which the phenyl moiety is optionally substituted by one or two of halogen, ortho -nitro, meta - or para -methoxy, methyl or NR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently hydrogen or C₁₋₆ alkyl or R₁₂ and R₁₃ together are C₂₋₆ polymethylene or the phenyl moiety is 3,4-disubstituted by methylenedioxy or ethylenedioxy; and R₇ is hydrogen or C₁₋₄ alkyl. The compounds of the present invention have anti-hypoxic activity and/or activity against cerebral oxygen deficiency and are therefore useful in treating cerebrovascular disorders and disorders associated with cerebral senility. Suitable examples of R₁ include hydrogen, methyl, ethyl, n- and iso - propyl, n -, sec -, iso - and tert -butyl, methoxy, ethoxy, fluoro and chloro. R₁ is preferably hydrogen or methyl, most preferably hydrogen. R₂ and R₃ preferably together represent a bond. R₄ is preferably C₁₋₆ alkyl or COR₈ where R₈ is as defined above. Examples of R₄ include methyl, ethyl, n -and iso -propyl, n -, iso -, sec - and t -butyl, and methoxy carbonyl. R₅ is preferably hydrogen or C₁₋₆ alkyl. Examples of R₅ include hydrogen, methyl and ethyl. Examples of R₆ include benzyl, phenethyl or 1-methyl-2-phenethyl in which the phenyl moiety is optionally substituted by one or two of fluoro, chloro, bromo, amino, methylamino, ethylamino, neo -pentylamino, dimethylamino, diethylamino, di-isopropylamino, 1-piperidyl, 1-pyrrolidyl, ortho -nitro, meta - or para -methoxy or methyl, or 3,4-disubstituted by methylenedioxy. Preferably R₆ is benzyl or 1-methyl-2-phenylethyl, optionally monosubstituted in the phenyl moiety by NR₁₂R₁₃. Suitable examples of R₇ include hydrogen, methyl, ethyl, n - and iso -propyl, n -, sec -, iso - and tert -butyl. The compounds of formula (I) can form acid addition salts with acids, such as the conventional pharmaceutically acceptable acids, for example hydrochloric, hydrobromic, phosphoric, acetic, fumaric, salicylic, citric, lactic, mandelic, tartaric, oxalic and methanesulphonic. There is a favourable group of compounds within formula (I) of formula (II): wherein R₁, R₂, R₃, R₄, R₅ and R₇ are as defined in formula (I) and R₆¹ is phenyl C₁₋₇ alkyl optionally monosubstituted by NR₁₂R₁₃ where R₁₂ and R₁₃ are as defined in formula (I). Suitable and preferred values for the remaining variables in formula (II) are as described for the corresponding variables under formula (I). There is a sub-group of compounds within formula (II) of formula (IIa): wherein R₁, R₂, R₃, R₄, R₅ and R₇ are as defined in formula (I) and R₆² is phenyl C₁₋₄ alkyl optionally mono-substituted by NR₁₂R₁₃ where R₁₂ and R₁₃ are as defined in formula (II). Suitable and preferred values for the variables are as described for the corresponding variables under formula (1). Preferably R₁ is hydrogen. Preferably R₂ and R₃ represent a bond. Preferably R₄ is methyl or methoxycarbonyl. Preferably R₅ is hydrogen, methyl or ethyl. Preferably R₆² is benzyl or 1-methyl-2-phenylethyl optionally meta - or para -substituted by amino optionally substituted by one or two methyl or ethyl groups. Preferably R₇ is hydrogen. Where compounds of formula (I) can exist in more than one stereoisomeric form, the invention extends to each of these forms and to mixtures thereof. The invention further provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, which process comprises the alkylation of a compound of formula (III): wherein R₁, R₂ and R₃ are as defined in formula (I), R₄' and R₅' are R₄ or R₅ as defined in formula (I) or groups convertible thereto, to give a compound of formula (IV): where R₆' is R₆ as defined with any amino substituent optionally protected, or containing an amine precursor, and thereafter, optionally and as necessary, de-protecting any protected amino substituent or converting any amine precursor to amine in R₆', converting R₄' and/or R₅' when other than R₄ or R₅ into R₄ and/or R₅, interconverting R₄, R₅, R₆ and/or R₇ to other R₄, R₅, R₆ or R₇, reducing the R₂/R₃ bond, and/or forming a pharmaceutically acceptable salt. Suitable examples of R₆' convertible to R₆ include phenyl C₁₋₇ alkyl substituted in the phenyl moiety by a protected amino group or an amine precursor. The alkylation of the compound of formula (III) may be carried out by conventional amine alkylation or, more preferably, by acylation followed by reduction of the amide, or by reductive alkylation. Acylation may be carried out using the appropriate acyl chloride or anhydride and the subsequent reduction of the resulting amide with LiAlH₄, in a suitable inert solvent such as tetrahydrofuran, and optionally in the presence of AlCl₃. The reductive alkylation procedure may be carried out by heating with the aldehyde or ketone in an organic acid, such as acetic acid, then reducing the product in situ using an alkaline borohydride such as sodium borohydride or cyanoborohydride. The reaction can also be carried out in an alcohol, in which case the reduction can be carried out either chemically, for example with a borane such as trimethylammoniumborane or an alkaline borohydride or with hydrogen in the presence of a catalyst such as Raney nickel. It is also possible to use an aprotic solvent, for example an aromatic solvent such as benzene or toluene, the water formed being eliminated either at room temperature by means of a drying-agent or under reflux heating of the solvent by means of a Dean-Stark water-separator; the reduction can then be expediently carried out with hydrogen in the presence of a catalyst such as palladiated carbon or platinum oxide. These methods may be subject to certain limitations, depending on the nature of the aldehyde or ketone used. It is also possible to use a more universal method. For example, the compound of formula (III) and the aldehyde or ketone to be condensed are dissolved in a mixture of solvents which can advantageously be a methanol-dichloromethane mixture in the presence of a complex reducing agent such as quaternary ammonium cyanoborohydride or, more simply, an alkaline cyanoborohydride solubilised by a phase-transfer agent, for example sodium cyanoborohydride and aliquat® 336 (Cf. Hutchins, R.O. and Markowitz, M., Journal of Organic Chemistry 1981, 46 , pp.3571-3574). It will be appreciated that compounds of formula (I) wherein R₆ is substituted phenyl C₁₋₇ alkyl may be interconverted by conventional procedures including aromatic substituents. Thus, when a phenyl moiety in R₆' is substituted by an amine precursor, conversion of the precursor to amino may be carried out conventionally. For example, when the precursor is nitro, the conversion may be carried out by catalytic reduction, e.g. in the presence of Raney nickel. When R₆' is an R₆ group with a protected amino moiety, the protecting group may be removed conventionally or the protected R₆ be converted to the desired R₆ group by reduction e.g. with LiAlH₄ and AlCl₃. Substitution of the resulting primary amine by R₁₂ and R₁₃ may be carried out by conventional procedures. Thus conventional amine alkylation, acylation followed by reduction, or reductive alkylation may be employed as described above for the alkylation of the compound of formula (III). When the acylation/reduction procedure is adopted to give an intermediate where the amine of formula (III) is substituted by phenyl C₁₋₇ alkanoyl substituted by alkanoylamino, simultaneous reduction of both alkanoyl moieties may be carried out to give the desired compound of formula (I). The reduction of the R₂/R₃ bond may be carried out conventionally by the use of an alkaline borohydride in a polar aprotic solvent such as dimethylsulphoxide or by nitromethane in the presence of a strong organic acid such as methanesulphonic acid or in pure trifluoroacetic acid. Alternatively the bond may be reduced catalytically with hydrogen over platinum oxide catalyst in a solvent permitting protonation of the indolic nitrogen, such as ethanol containing fluoroboric acid or acetic acid containing trifluoroacetic acid. Groups R₅' convertible to R₅ include conventional amino protecting groups such as C₁₋₆ alkoxy carbonyl. aryloxycarbonyl, C₁₋₆ alkanoyl or phenyl C₁₋₄ alkanoyl, which may be removed by conventional procedures or, where appropriate converted direct to the correspondong R₅ group by reduction with LiAlH₄ and AlCl₃. Groups R₄' convertible to R₄ include the groups mentioned above for R₅' and groups COR₈' where R₈' is protected amino, which can be converted direct to the corresponding group R₄ as described above for R₅. Interconversion of R₄ and R₅ may be performed conventionally, as for example by the conversion of hydrogen to alkyl by conventional alkylation as described for the compound of formula (III), and the interconvertion of groups R₈, R₉ and R₁₀ in R₅ by convention esterification/de-esterification and amine alkylation, respectively. It will be appreciated that these conversions may take place in any desired or necessary order. Pharmaceutically acceptable salts of the compounds of formula (I) may be formed conventionally by reaction with the appropriate acid such as described above formula (I). Compounds of formula (III) are known or may be prepared by any of the appropriate methods in conventional indole chemistry. Thus, the aminoethyl moiety may be introduced into the compound of formula (V): or the aminoethyl moiety may be incorporated into the indole during the indole synthesis. Examples of the former method include: i) Mannich reaction of the compound of formula (V) with formaldehyde and dimethylamine, followed by treatment with cyanide and reduction of the nitrile by standard methods such as hydrogenation with PtO₂ in acetic acid or Raney nickel in alcohol and ammonia; or reduction with LiAlH₄/AlCl₃; ii) The reaction of the compound of formula (V) with 2-nitroethyl acetate and subsequent reduction of the nitro group by standard methods; iii) The conversion of the compound of formula (V) to the indolyl magnesium halide and reaction with α-haloacetonitrile followed by reduction of the nitrile as in i) above. Compounds of formula (III) may also be prepared from compounds of formula (V) via a compound of formula (VI): where R₁, R₄' and R₅' are as defined in formula (III) and Y is a conventional amine precursor. Suitable examples for Y include CN, COQ where Q is H or a leaving group such as halo, C₁₋₄ alkoxy or carboxylic acyloxy, and CH₂L where L is CON₃, N₃, NO₂ or X where X is a leaving group such as hydroxy, halo, C₁₋₄ alkoxy, C₁₋₄ alkanoyloxy, C₁₋₄ alkoxycarbonyloxy, tosyloxy or mesyloxy. The compound of formula (VI) may be prepared conventionally with regard to the group Y. Thus, for example, a compound of formula (VI) may be obtained by reaction of the compound of formula (V) with: (i) ClCOCOR₁₄, where R₁₄ is alkoxy such as ethoxy or halo such as chloro, followed by reduction with LiAlH₄ to give a compound of formula (VI) where Y is -CH₂OH, which may subsequently be reacted with azide ion to give the corresponding compound where Y is -CH₂N₃; (ii) CH₂=CH-R₁₅, where R₁₅ is a 1-carbonyl containing group or cyano, under basic conditions, followed by hydrolysis and reaction on the resulting acid group by azide ion as described above, to give a compound of formula (VI) where Y is -CH₂CON₃; (iii) formaldehyde in the presence of dimethylamine followed by reaction of cyanide ion on the resulting tertiary amine, if necessary after quaternization, to give a compound of formula (VI) where Y is -CN, which may be converted to the compound where Y is -CHO by reaction with diisobutylaluminiumhydride or to the compond where Y is -COQ by hydrolysis of the nitrile under acid conditions to give the corresponding acid, followed by conversion of the hydroxyl group to a leaving group Q such as chloro with a chlorinating agent such as oxalyl chloride; (iv) CH₂=CHNO₂ under basic conditions to give a compound of formula (VI) where Y is -CH₂NO₂. The reaction converting the compound of formula (VI) into that of formula (III) may be carried out under the conventional conditions appropriate to the particular group Y in formula (VI). Thus, when Y is CH₂CON₃, the conversion is a Curtius degradation carried out conventionally,by heating in a dry inert solvent, such as benzene, and then subsequent hydrolysis of the thus formed isocyanate under acid conditions. When Y is CN, the conversion is a reduction to the primary amine, for example with a reducing agent such as diborane or LiAlH₄ at elevated temperature and in an inert solvent such as tetrahydrofuran, or with hydrogen over Raney nickel in the presence of ammonia at ambient temperature in a polar solvent such as methanol. When Y is CHO, the conversion is a condensation with hydroxylamine followed by reduction of the thus formed oxime over a metallic catalyst, or is a reductive amination with a primary or secondary amine using a reducing agent such as NaBH₃CN in a polar solvent such as CH₂Cl₂/CH₃OH at elevated temperature. Alternatively the intermediate imine may be prepared in a non polar solvent such as benzene in the presence of an acid catalyst e.g. p-toluenesulphonic acid and reduced with a reducing agent such as NaBH₄. When Y is COQ where Q is a leaving group, the conversion is a nucleophilic substitution by ammonia or a primary or secondary amine under conventional conditions appropriate for leaving group Q, followed by reduction of the resulting amide with e.g. LiAlH₄ in an inert solvent such as tetrahydrofuran at elevated temperature followed by work up. For example, when Q is halo such as chloro, the nucleophilic substitution may be carried out at ambient or lower temperature in the presence of an acid acceptor such as triethylamine in a polar solvent such as CH₂Cl₂, followed by work up to give the amide which may be reduced as just described. When Y is CH₂N₃, the conversion is a reduction of the azide to the primary amine with e.g. hydrogen over a metallic catalyst. When Y is CH₂NO₂, the conversion is a reduction of the nitro group to the primary amine with a reducing agent such as LiAlH₄, or hydrogen over Raney nickel or Pd/C catalyst in a polar solvent such as ethanol. When Y is CH₂X, the conversion is a nucleophilic substitution by ammonia or a primary or secondary amine or azide ion, under conventional conditions appropriate for the leaving group X. Thus, when X is hydroxy, it is first converted into a good leaving group such as mesylate or tosylate (using mesyl or tosyl chloride respectively) or chloride (using SOCl₂). The nucleophilic substitution may be carried out at elevated temperature in a polar solvent such as acetonitrile in the presence of an acid acceptor such as diisopropyl ethylamine. Alternatively, the leaving group may be substituted by nitrile to yield a compound of formula (VI) where Y=CH₂CN. Hydrolysis and conversion by conventional methods yields a compound where Y=CH₂CON₃ via the acid by the formation of the acid chloride followed by reaction of azide ion. Alternatively the aminoethyl moiety may be incorporated during the indole synthesis, for example, by the reaction of phenylhydrazine with: a) ethyl-2-oxo-5-phthalimidovalerate to give a compound followed by hydrolysis with hydrazine; b) diethyl-2-oxo-5-carbethoxamidoadipate to give a compound followed by saponification and decarboxylation; c) 6,6-Dimethyl-5-oxo-heptanoic acid. The resulting acid may be converted to the amine by the Curtius degradation via the -CON₃ compound described above; d) keto acids of general formula followed by reduction of the double bond and conversion of the acid to the amine as in c) above. For further examples of known indole synthesis procedures for the preparation of compounds of formulae (III) and (V), see R.J.Sundberg, "The Chemistry of Indoles", Academic Press, New York, N.Y., 1970, and R.K.Brown in "Indoles," Part 1, W.J.Houlihan, Ed., Wiley-Interscience, New York, N.Y., 1972, and Paul G.Grassmann et al J.Am.Chem.Soc . 1974, 96, 5495-5517. Compounds of formula (III) where R₂ and R₃ are hydrogen may be prepared from the corresponding indole by reduction as described above for the reduction of an R₂/R₃ bond in the compound of formula (IV). In the formulae (V) and (VI) above, the variables are as defined in formula (I) or formula (III). The invention further provides a process for the preparation of a compound of formula (I), or a pharmaceutically acceptable salt thereof, which process comprises the conversion of a compound of formula (VII): where R₁, R₄' and R₅' are as defined in formula (V) and W is a group convertible to (CH₂)₂NR₆''R₇' where R₆'' is R₆ as defined in formula (I) or a group convertible thereto and R₇' is R₇ as defined in formula (I) or an amino protecting group, into a compound of formula (VIIa): and thereafter, optionally or as necessary, converting R₄', R₅', R₆'' and/or R₇' when other than R₄, R₅, R₆ or R₇ into R₄, R₅, R₆ or R₇, interconverting R₄, R₅, R₆ and/or R₇ to other R₄, R₅, R₆ or R₇, reducing the R₂/R₃ bond and/or forming a pharmaceutically acceptable salt. Examples of R₆'' convertible to R₆ include hydrogen, and R₆' as defined in formula (IV) or phenyl C₁₋₇ alkanoyl optionally substituted by a substituent defined for R₆ with any amino substituent optionally protected or by an amine precursor. Examples of W include: (i) hydrogen, where the conversion reaction is as described above for the preparation of a compound of formula (III) from a compound of formula (V) followed by the alkylation of the compound of formula (III) as described; (ii) CH₂Y where Y is a conventional amine precursor such as exemplified above, which may be converted to the primary amine of formula (VIIa) where R₆'' and R₇' are both hydrogen as described for the conversion of the compound of formula (VI) and subsequently alkylated as described for the alkylation of the compound of formula (III). Alternatively, where the conversion employs a primary or secondary amine for reaction with the compound of formula (VII), a compound of formula (VIIa) may be obtained where R₆'' is R₆' as previously defined; (iii)COCOL where L is a leaving group such as halo, which may be converted to the group (CH₂)₂ NR₆'' R₇' by reaction with the appropriate substituted amines followed by reduction with a suitable reducing agent such as lithium aluminium hydride, as generally described in GB-A-781 390. (iv) a group selected from and which may be converted to the primary amine as described above. In the case where R₇' is an amino protecting group such as C₁₋₆ alkoxycarbonyl, aryloxycarbonyl, C₁₋₆ alkanoyl or phenyl C₁₋₇ alkanoyl, the protecting group may be removed by conventional procedures. The interconversion of an R₇ hydrogen atom may be carried out by conventional amine alkylation as described above for the alkylation of the compound of formula (III). Conversion of groups R₄' and R₅' in the compound of formula (VIIa), and interconversion of groups R₁, R₂, R₃, R₄, R₅ and R₆ may be carried out as described above for the conversion of the corresponding variables in the compound of formula (IV). It will be appreciated that the conversions and interconversions of variables in the compound of formula (VIIa) may take place in any desired or necessary order. The invention further provides a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions. In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose. Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate. The solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating. Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents. For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound. The compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of such disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and the relative efficacy of the compound. However, as a general guide suitable unit doses may be 0.05 to 100 mg. for example 0.2 to 50 mg; and such unit doses may be administered more than once a day, for example two or three times a day, so that the total daily dosage is in the range of about 0.1 to 100 mg/kg; and such therapy may extend for a number of weeks or months. At the above indicated dosage range, no toxicological effects are indicated for the compounds of the invention. In a further aspect the invention provides a compound of formula (I) for use as an active therapeutic substance. The invention further provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use in the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility. The following examples illustrate the invention and the following descriptions illustrate the preparation of intermediates thereto. Description 1 1,2-Dimethyl-3-(aminoethyl)indole hydrochloride (D1) Compound D1 was prepared by conventional procedures from 1,2-dimethylindole. D1 is described in JP-590 73568-A (Kawaken Fine Chemicals Co. Ltd). Description 2 2-Methyl-3-(aminoethyl)indole(D2) Compound D2 was prepared by conventional procedures from 2-methylindole. D2 is described by Grandberg, I.I. and Bobrova, N.I. in Khim. Geterotsikl. Soedin . 1974,8,1085. Description 3 2-Methoxycarbonyl-3-(aminoethyl)indole (D3) a) 2-Methoxycarbonylindole 50 g Indole-2-carboxylic acid were stirred with 400 ml methanol/10% H₂SO₄ for 48 hours. The resulting crystals were filtered off and washed with methanol giving 51.3 g product. b) 3-Dimethylaminomethyl-2-methoxycarbonylindole To 51 g ester from a) was added a mixture of 38 ml dimethylamine, 40 ml acetic acid and 23.5 ml formaldehyde (35% in water). After 20 hours stirring at 80 o C the mixture was cooled and the product isolated by acid-base separation. c) 2-Methoxycarbonyl-3-cyanomethylindole 40.6 g Product from b) were dissolved in 300 ml DMSO and 14.5 ml ethylbromide were added. After 10 minutes, 11.4 g KCN were added and the mixture was stirred for 48 hours. The reaction mixture was poured into citric acid and extracted with CH₂Cl₂. The solvent was evaporated to give 26 g yellow residue. d) Title compound 26 g Product from c) were dissolved in 1 litre acetic acid, 2 g Pt/C were added and the mixture was hydrogenated at 70 bar for 2 days. The catalyst was filtered off and the solvent evaporated. Acid-base separation yielded 20.3 g D3 as an oil. Nmr: (d₆-DMSO) δ: 7.85-6.95[4]m; 3.93[3]s; 3.40-2.70[4]m. Example 1 1,2-Dimethyl-3-[2-(1-methyl-2-phenylethyl)aminoethyl]indole hydrochloride (E1) 4 g (0.018 moles) D1 were dissolved in 100 ml methanol. Molecular-sieves of 3Å were added and the mixture was stirred for ½ hour. Then 2.4 g (0.018 moles) phenylacetone and 1.2 g (0.018 moles) NaBH₃CN were added. After stirring overnight the molecular sieves were filtered off, the solvent was evaporated, and the residue was dissolved in CH₂Cl₂, washed with sodium carbonate solution and dried over Na₂SO₄. The solvent was evaporated and methanol/HCl was added. The mixture was concentrated and the product crystallised from ethylacetate. Yield: 2.9 g; m.p. : 210 o C Calc. C 73.55 H 7.94 N 8.17 Cl 10.34 found: C 73.68 H 7.89 N 8.42 Cl 10.46 Nmr: (CDCl₃/d₆-DMSO): δ : 9.9[2]s,broad; 7.63[1]m; 7.15[8]m; 3.58[3]s; 3.30[7]m; 2.35[3] s; 1.41[3]d, J=6.3 Example 2 1,2-Dimethyl-3-[2-(4-dimethylaminobenzyl)aminoethyl]indole dihydrochloride, hemihydrate (E2) a) 3.4 g (0.015 moles) D1 were dissolved in 60ml CH₂Cl₂, 10 ml triethylamine and 1.2 equivalents of 4-dimethylaminobenzoic-acid chloride were added with cooling. The mixture was stirred at room temperature for ½ hour and then poured into sodium carbonate solution. The product was extracted with CH₂Cl₂, washed with citric acid and dried over Na₂SO₄, to give 4.7 g amide 1,2-dimethyl-3-[2-(4-dimethylaminobenzoyl) aminoethyl]indole. b) 600 mg (0.015 moles) LiAlH₄ were suspended in 40 ml THF. The amide from a) dissolved in 10ml THF, was added. The mixture was refluxed for 4 hours. After cooling, water was added with caution. Aluminium hydroxide was filtered off and washed with THF. The filtrate was concentrated, the residue dissolved in CH₂Cl₂, washed with water and dried over Na₂SO₄. The solvent was evaporated and the hydrochloride was formed with HCl/methanol. The product was crystallized from CH₂Cl₂/isopropanol. Yield: 2.2 g, m.p.: 192 o C (dec.) Nmr: (d₆-DMSO) δ: 9.65[2]s,broad; 7.35[8]m; 4.12[2]tr; 3.64[3]s; 3.01[10]m; 2.36[3]s; calc.: C 62.53 H 7.49 N 10.42 Cl 17.58 found: C 62.57 H 7.28 N 10.33 Cl 17.29 Example 3 2-Methyl-3-[2-(1-methyl-2-phenylethyl)aminoethyl]indole hydrochloride (E3) 6.7 g (0.032 moles) 2-methyltryptamine were reacted with 4.8 g phenylacetone and 2.3 g NaBH₃CN according to Example 1. The crude product was purified by column-chromatography (CH₂Cl₂), converted to the hydrochloride with HCl/methanol and crystallized from ethylacetate. Yield: 3.5 g, m.p.: 191 o C Nmr: (CDCl₃/d₆ - DMSO) δ: 10.40[1]s; 9.40[2]s, broad; 7.52[1]m; 7.24[6]m; 7.00[2]m; 3.25[7]m; 2.42[3]s; 1.25[3]d, J=6.3 calc.: C 73.04 H 7.66 N 8.25 Cl 10.78 found: C 72.89 H 7.59 N 8.61 Cl 10.61 Example 4 2-Methyl-3-[2-(4-dimethylaminobenzyl)aminoethyl]indole dihydrochloride (E4) 8.5 g (0.049 mol) 2-Methyltryptamine (D2) were reacted with 8.7 g (0.058 mol) 4-dimethylaminobenzaldehyde and 3.1 g (0.05 mol) NaBH₃CN according to Example 1. The crude product was purified by column chromatography (CH₂Cl₂/5% CH₃OH), converted to the hydrochloride with HCl/methanol and cryatallised from isopropanol. NMR: (d6 - DMSO) δ: 10.90 [1] s, broad; 9.60 [2] s, broad; 7.30 [9] m; 4.12 [2] m; 3.02 [10] m; 2.33 [3] s. Example 5 2-Methoxycarbonyl-3-[2-(1-methyl-2-phenylethyl)aminoethyl]indole hydrochloride (E5) 10 g (0.046 mol) 2-Methoxycarbonyl-tryptamine (D3) were reacted with 6.8 g phenylacetone and 3.2 g NaBH₃CN according to Example 1. The product was purified by column chromatography (CH₂Cl₂/5% CH₃OH), converted to the hydrochloride and crystallised from ethylacetate. Yield: 3.5 g m.p.: 215 o C NMR: (d6 - DMSO) δ: 11.76 [1], s; 9.56 [2] s, broad; 7.90 [1] m; 7.30 [8] m; 3.93 [3] s; 3.75 - 2.60 [7] m; 1.16 [3] d. J= 6.4 calc.: C 67.64 H 6.76 N 7.51 Cl 9.51 found: C 66.79 H 6.68 N 7.52 Cl 9.11 Example 6 2-Methoxycarbonyl-3-[2-(4-dimethylaminobenzyl)aminoethyl]indole dihydrochloride (E6) The product was synthesized according to Example 1 from 2-methoxycarbonyltryptamine (D3), 4-dimethylaminobenzaldehyde and NaBH₃CN. m.p.: 215 o C NMR: d6- DMSO δ: 11.73 [1] s; 9.50 [2] s, broad; 7.40 [9] m; 4.11 [2] m; 3.89 [3] s; 3.50 [2] m; 3.00 [8] m. calc.: C 59.44 H 6.41 N 9.90 Cl 16.71 found: C 59.56 H 6.46 N 9.87 Cl 16.35 Pharmacological Data Triethyltin-induced cerebral oedema in the rat. The cerebral oedema is induced by oral administrations repeated for 5 consecutive days - one administration per day - of triethyltin chloride at a dose of 2 mg/kg. The study substances are also administered orally twice daily as aqueous solution or suspension at a dose of 1 ml/100 g body-weight; these administrations are given during the 5 days of intoxication with tin. Three groups of 10 male specific pathogen-free (SPF) Wistar rats of 280 ± 10 g body-weight are used for each compound studied: 1 control group 1 group intoxicated with triethyltin 1 group intoxicated with triethyltin and treated with the studied compound. The rats are killed on the evening of the fifth day; the brain is removed, weighed fresh and after dessication to constant weight and the water content of each brain is calculated: [H₂O] = fresh weight - dry weight. The following are then calculated: the mean water content (M ± Sm%) of each group; the protection index P due to the administered compound: The results are shown in Table 1. Compound dosage % reduction significance E1 12.5 mg/kg 65 0.01 E2 50 mg/kg 100 0.01 E3 12.5 mg/kg 42 0.01 The significance was evaluated by the student t-test.

Claims: Claims for the following Contracting States : BE, CH, DE, FR, GB, GR, IT, LI, LU, NL, SE The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R₁ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkozy or halogen; R₂ and R₃ are both hydrogen or together represent a bond; R₄ is selected from C₁₋₆ alkyl, phenyl, phenyl C₁₋₄ alkyl, COR₈ where R₈ is hydroxy, C₁₋₆ alkoxy or NR₉R₁₀ where R₉ and R₁₀ are independently hydrogen or C₁₋₄ alkyl and CH₂OR₁₁ where R₁₁ is hydrogen, C₁₋₄ alkyl or C₁₋₄ alkanoyl; R₅ is hydrogen, C₁₋₆ alkyl or phenyl C₁₋₄ alkyl; R₆ is phenyl C₁₋₇ alkyl in which the phenyl moiety is optionally substituted by one or two of halogen, ortho -nitro, meta -or para -methoxy, methyl or NR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently hydrogen or C₁₆ alkyl or R₁₂ and R₁₃together are C₂₋₆ polymethylene or the phenyl moiety is 3,4-disubstituted by methylenedioxy or ethylenedioxy; and R₇ is hydrogen or C₁₋₄ alkyl; for the manufacture of a medicament for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility. A compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R₁ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy or halogen; R₂ and R₃ are both hydrogen or together represent a bond; R₄ is selected from C₁₋₆ alkyl, phenyl, phenyl C₁₋₄ alkyl, COR₈ where R₈ is hydroxy, C₁₋₆ alkoxy or NR₉R₁₀ where R₉ and R₁₀ are independently hydrogen or C₁₋₄ alkyl and CH₂OR₁₁ where R₁₁ is hydrogen, C₁₋₄ alkyl or C₁₋₄ alkanoyl; R₅ is hydrogen, C₁₋₆ alkyl or phenyl C₁₋₄ alkyl; R₆ is phenyl C₁₋₇ alkyl in which the phenyl moiety is optionally substituted by one or two of NR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently hydrogen or C₁₋₆ alkyl or R₁₂ and R₁₃ together are C₂₋₆ polymethylene; and R₇ is hydrogen or C₁₋₄ alkyl; excluding 7-methoxy-2-benzyl-3-(2-N-benzylaminoethyl)indole, 2-hexyl-3-(2-N-phenethylaminoethyl)indole and 3-[2-(N-benzyl-N-t-butylamino)ethyl]-5-methoxy-2-methylindole. A compound according to claim 2 of formula (II): wherein R₁, R₂, R₃, R₄, R₅ and R₇ are as defined in claim 2 and R₆¹ is phenyl C₁₋₇ alkyl optionally monosubstituted by NR₁₂R₁₃ where R₁₂ and R₁₃ are as defined in claim 2. A compound according to claim 2 or 3 of formula (IIa): wherein R₁, R₂, R₃, R₄, R₅ and R₇ are as defined in claim 2 and R₆² is phenyl C₁₋₄ alkyl optionally mono-substituted by NR₁₂R₁₃ where R₁₂ and R₁₃ are as defined in claim 2. A compound according to any of claims 2 to 4 wherein R₁ is hydrogen. A compound according to any of claims 2 to 5 wherein R₂ and R₃ represent a bond. A compound according to any of claims 2 to 6 wherein R₄ is methyl or methoxycarbonyl. A compound according to any of claims 2 to 7 wherein R₅ is hydrogen, methyl or ethyl. A compound according to any of claims 2 to 8 wherein R₆, R₆¹ or R₆² is benzyl or 1-methyl-2-phenylethyl optionally meta - or para - substituted by amino optionally substituted by one or two methyl or ethyl groups. 2-methyl-3-[2-(4-dimethylaminobenzyl)aminoethyl] indole, or 2-methoxycarbonyl-3-[2-(4-dimethylaminobenzyl)amino ethyl] indole, or a pharmaceutically acceptable salt thereof. A pharmaceutical composition, comprising a compound of formula (I), as defined in claim 2 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier thereof. A compound of formula (I) as defined in claim 2 or a pharmaceutically acceptable salt thereof, for use as an active therapeutic substance. A compound of formula (I) as defined in claim 2 or a pharmaceutically acceptable salt thereof for use in the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility. A process for the preparation of a compound according to claim 2, which process comprises the conversion of a compound of formula (VII): where R₁ is as defined in claim 2, R₄' and R₅' are R₄ or R₅ as defined in claim 2 or groups convertible thereto and W is a group convertible to (CH₂)₂ NR₆''R₇' where R₆'' is R₆ as defined in claim 2 or a group convertible thereto and R₇' is R₇ as defined in claim 2 or an amino protecting group, into a compound of formula (VIIa): and thereafter, optionally or as necessary, converting R₄', R₅', R₆'' and/or R₇' when other than R₄, R₅, R₆ or R₇ into R₄, R₅, R₆ or R₇, interconverting R₄, R₅, R₆ and/or R₇ to other R₄, R₅, R₆ or R₇, reducing the R₂/R₃ bond and/or forming a pharmaceutically acceptable salt. A process for the preparation of a compound according to claim 2, which process comprises the alkylation of a compound of formula (III): wherein R₁, R₂ and R₃ are as defined in claim 2, R₄' and R₅' are R₄ or R₅ as defined in claim 2 or groups convertible thereto, to give a compound of formula (IV): where R₆' is R₆ as defined in claim 2 with any amino substituent optionally protected, or containing an amine precursor, and thereafter, optionally and as necessary, de-protecting any protected amino substituent or converting any amine precursor to amine in R₆', converting R₄'and/or R₅'when other than R₄ or R₅ into R₄ and/or R₅, interconverting R₄, R₅, R₆ and/or R₇ to other R₄, R₅, R₆ or R₇, reducing the R₂/R₃ bond, and/or forming a pharmaceutically acceptable salt. A compound of formula (VIIa): wherein R₁, R₂ and R₃ are as defined in claim 2, R₄' and R₅' are R₄ or R₅ as defined in claim 2 or groups convertible thereto, R₆'' is R₆ as defined in claim 2 or a group convertible thereto and R₇' is R₇ as defined in claim 2 or an amino protecting group. 1,2-Dimethyl-3-[2-(4-dimethylaminobenzoyl) aminoethyl]indole. Claims for the following Contracting State : ES A process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R₁ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy or halogen; R₂ and R₃ are both hydrogen or together represent a bond; R₄ is selected from C₁₋₆ alkyl, phenyl, phenyl C₁₋₄ alkyl, COR₈ where R₈ is hydroxy, C₁₋₆ alkoxy or NR₉R₁₀ where R₉ and R₁₀ are independently hydrogen or C₁₋₄ alkyl and CH₂OR₁₁ where R₁₁ is hydrogen, C₁₋₄ alkyl or C₁₋₄ alkanoyl; R₅ is hydrogen, C₁₋₆ alkyl or phenyl C₁₋₄ alkyl; R₆ is phenyl C₁₋₇ alkyl in which the phenyl moiety is optionally substituted by one or two of NR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently hydrogen or C₁₋₆ alkyl or R₁₂ and R₁₃ together are C₂₋₆ polymethylene; and R₇ is hydrogen or C₁₋₄ alkyl; excluding 7-methoxy-2-benzyl-3-(2-N-benzylaminoethyl)indole, 2-hexyl-3-(2-N-phenethylaminoethyl)indole and 3-[2-(N-benzyl-N-t-butylamino)ethyl]-5-methoxy-2-methylindole; which process comprises the conversion of a compound of formula (VII): where R₁ is as defined above, R₄' and R₅' are R₄ or R₅ as defined above or groups convertible thereto and W is a group convertible to (CH₂)₂ NR₆''R₇' where R₆'' is R₆ as defined above or a group convertible thereto and R₇' is R₇ as defined above or an amino protecting group, into a compound of formula (VIIa): and thereafter, optionally or as necessary, converting R₄', R₅', R₆'' and/or R₇' when other than R₄, R₅, R₆ or R₇ into R₄, R₅, R₆ or R₇, interconverting R₄, R₅, R₆ and/or R₇ to other R₄, R₅, R₆ or R₇, reducing the R₂/R₃ bond and/or forming a pharmaceutically acceptable salt. A process according to claim 1 for preparing a compound of formula (II): wherein R₁, R₂, R₃, R₄, R₅ and R₇ are as defined in claim 2 and R₆¹ is phenyl C₁₋₇ alkyl optionally monosubstituted by NR₁₂R₁₃ where R₁₂ and R₁₃ are as defined in claim 2. A process according to claim 1 or 2 for preparing a compound of formula (IIa): wherein R₁, R₂, R₃, R₄, R₅ and R₇ are as defined in claim 2 and R₆² is phenyl C₁₋₄ alkyl optionally mono-substituted by NR₁₂R₁₃ where R₁₂ and R₁₃ are as defined in claim 1. A process according to any of claims 1 to 3 for preparing a compound wherein R₁ is hydrogen. A process according to any of claims 1 to 4 for preparing a compound wherein R₂ and R₃ represent a bond. A process according to any of claims 1 to 5 for preparing a compound wherein R₄ is methyl or methoxycarbonyl. A process according to any of claims 1 to 6 for preparing a compound wherein R₅ is hydrogen, methyl or ethyl. A process according to any of claims 1 to 7 for preparing a compound wherein R₆, R₆¹ or R₆² is benzyl or 1-methyl-2-phenylethyl optionally meta - or para - substituted by amino optionally substituted by one or two methyl or ethyl groups. A process according to claim 1 for preparing 2-methyl-3-[2-(4-dimethylaminobenzyl)aminoethyl] indole, or 2-methoxycarbonyl-3-[2-(4-dimethylaminobenzyl)amino ethyl] indole, or a pharmaceutically acceptable salt thereof. A process for the preparation of a compound according to claim 1, which process comprises the alkylation of a compound of formula (III): wherein R₁, R₂ and R₃ are as defined in claim 1, R₄' and R₅' are R₄ or R₅ as defined in claim 1 or groups convertible thereto, to give a compound of formula (IV): where R₆' is R₆ as defined in claim 1 with any amino substituent optionally protected, or containing an amine precursor, and thereafter, optionally and as necessary, de-protecting any protected amino substituent or converting any amine precursor to amine in R₆', converting R₄'and/or R₅'when other than R₄ or R₅ into R₄ and/or R₅, interconverting R₄, R₅, R₆ and/or R₇ to other R₄, R₅, R₆ or R₇, reducing the R₂/R₃ bond, and/or forming a pharmaceutically acceptable salt. The use of a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein: R₁ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkoxy or halogen; R₂ and R₃ are both hydrogen or together represent a bond; R₄ is selected from C₁₋₆ alkyl, phenyl, phenyl C₁₋₄ alkyl, COR₈ where R₈ is hydroxy, C₁₋₆ alkoxy or NR₉R₁₀ where R₉ and R₁₀ are independently hydrogen or C₁₋₄ alkyl and CH₂OR₁₁ where R₁₁ is hydrogen, C₁₋₄ alkyl or C₁₋₄ alkanoyl; R₅ is hydrogen, C₁₋₆ alkyl or phenyl C₁₋₄ alkyl; R₆ is phenyl C₁₋₇ alkyl in which the phenyl moiety is optionally substituted by one or two of halogen, ortho -nitro, meta -or para -methoxy, methyl or NR₁₂R₁₃ wherein R₁₂ and R₁₃ are independently hydrogen or C₁₋₆ alkyl or R₁₂ and R₁₃together are C₂₋₆ polymethylene or the phenyl moiety is 3,4-disubstituted by methylenedioxy or ethylenedioxy; and R₇ is hydrogen or C₁₋₄ alkyl; for the manufacture of a medicament for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility.

Inventors: HOELTJE, DAGMAR, THIELKE, DIETRICH
Applicants: SMITHKLINE BEECHAM PHARMA GMBH
Application year: 1986
Main classification: A61K31
IPC codes: C07D209, A61K31, A61P9